HURA
TuHURA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.14
+1.90%Aug 25, 2026, 00:00 UTC
Parabilis Medicines, Inc. appointed Craig Tendler, M.D., as a director, effective August 22, 2026, and granted him a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share.
Aug 19, 2026, 00:00 UTC
TuHURA Biosciences, Inc. issued 1,878,287 shares of common stock to Parkview Holdings One LLC as a loan fee in connection with a $50 million revolving credit facility, relying on Section 4(a)(2) and/or Regulation D exemptions.
Aug 14, 2026, 15:05 UTC
TuHURA Biosciences outlined plans at the Canaccord Genuity Growth Conference for its late-stage immuno-oncology pipeline, including an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates.
Source:Aug 14, 2026, 11:45 UTC
TuHURA Biosciences reported its financial results for the second quarter ended June 30, 2026.
Source:Jun 15, 2026, 11:45 UTC
TuHURA Biosciences filed an Investigational New Drug application with the FDA for its TBS-2025 VISTA inhibiting antibody to treat AML and other blood cancers.
Source: